Clinical Trials Logo

Filter by:
NCT ID: NCT06405711 Not yet recruiting - Myopia, Progressive Clinical Trials

To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia

Start date: May 2024
Phase: N/A
Study type: Interventional

To confirm the efficacy of DIMS lenses in controlling myopia progression, we planned a prospective, single-centre, randomised, double-blind, controlled, non-inferiority clinical study.

NCT ID: NCT06405685 Recruiting - Pancreatic Cancer Clinical Trials

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Start date: April 27, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with AG in the treatment of pancreatic cancer with liver metastasis. Patients will receive Nimotuzumab plus AG as conversion therapy, and imaging assessments (according to RECIST V.1.1 criteria) will be performed every two cycles (every two months) of conversion therapy. The main endpoint is R0 resection rate. Additional end points included resection rates, overall survival (OS), objective response rate (ORR), safety, etc.

NCT ID: NCT06405659 Completed - Fever Clinical Trials

Immediate Fever During Anaesthesia Recovery After Surgical Procedure With Scoliosis

Start date: August 6, 2018
Phase:
Study type: Observational

Fever is a common clinical symptom in patients with postoperative scoliosis. However, there are rare reports of immediately fevers occurring following operative procedures.

NCT ID: NCT06405490 Recruiting - Advanced Cancer Clinical Trials

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

NCT ID: NCT06405425 Not yet recruiting - Clinical trials for Urothelial Carcinoma

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.

NCT ID: NCT06405321 Recruiting - Clinical trials for Hepatocellular Carcinoma

Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma

Start date: January 1, 2019
Phase:
Study type: Observational

This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.

NCT ID: NCT06405308 Completed - Rectal Cancer Clinical Trials

Robotic Natural Orifice Specimen Extraction Surgery Versus Robotic Transabdominal Specimen Extraction Surgery for Early-Stage Rectal Cancer

Start date: October 1, 2023
Phase:
Study type: Observational

A retrospective cohort study, conducted nationwide(China) and across multiple centers, aimed to compare the surgical quality and short-term outcomes of R-NOSES (robotic natural orifice specimen extraction surgery)with R-TSES (robotic transabdominal specimen extraction surgery) for early-stage rectal cancer.

NCT ID: NCT06405295 Not yet recruiting - Clinical trials for Early-stage Triple-negative Breast Cancer With BRCA1/2 Mutations

A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation

Start date: May 6, 2024
Phase:
Study type: Observational

Evaluation of the efficacy and safety of different adjuvant intensification regimens in early-stage BRCA1/2 mutant triple-negative breast cancer.

NCT ID: NCT06405256 Recruiting - Brain Metastases Clinical Trials

Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases

Start date: January 3, 2020
Phase:
Study type: Observational [Patient Registry]

This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)

NCT ID: NCT06405217 Recruiting - Clinical trials for Radiotherapy; Complications

Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

Subjects: patients with postoperative local recurrent or metastatic differentiated thyroid cancer . Experimental group: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days. Control group: Thyroid hormone withdraw for 4-6 weeks. The two groups were treated with radioiodine 131I after plasma thyroid stimulating hormone elevated (>30mU/L). The efficacy and adverse reactions were observed.